Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

CD123-Targeted Immunotherapeutics in September 2016 - R&D and Business Tracker for Bispecific Antibodies - Research and Markets

Research and Markets
Posted on: 28 Oct 16

Research and Markets has announced the addition of the "CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies" report to their offering.

This pdf report contains information about Bispecific Antibodies released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Bispecific Antibodies which is listed in the "also available" below.

Featured presentations of September 2016 include the pipeline of CD123-targeted immunotherapeutics, the profile of Swiss pharmaceutical company Neovii Pharmaceuticals and the bispecific antibody profile of AMV-564 from Amphivena Therapeutics.

The September 2016 issue of our R&D and Business Tracker service about Bispecific Antibodies covers:

- T-Cell redirecting bispecific cancer antibodies

- NK cell redirecting bispecific cancer antibodies

- Bispecific immuno-oncology antibodies

- Bispecific tumor antigens targeted cancer antibodies

- Bispecific antibodies for inflammatory & autoimmune diseases

- Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases

The monthly update report about Bispecific Antibodies contains:

R&D and Technology Tracker

- Pipeline changes

- Regulatory news

- Technology validations

- Manufacturing news

Business Tracker for:

- Company updates

- Collaboration

- Licensing

- Merger & acquisitions

- Financing

Clinical Trial Tracker

Scientific Publication Tracker

Featured Bispecific Antibody Profile: AMV-564

Featured Company Profile: Neovii Pharmaceuticals

Featured Target or Technology Pipeline: CD123-Targeted Immunotherapeutics

CD123-Targeted Immunotherapeutics:

- Antibody-Drug Conjugates

- Immunotoxins

- Fc-Engineered Antibodies

- T-cell Redirecting Bispecific Antibodies

- CAR T-Cells

Information about the CD123-Targeted Immunotherapeutics pipeline is provided in a tabular format and fully referenced.

For more information about this report visit

View source version on

Business Wire

Last updated on: 28/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.